JP2009535430A

JP2009535430A - Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用

Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用 Download PDF

Info

Publication number: JP2009535430A
Authority: JP; Japan
Prior art keywords: glucocorticoid receptor; receptor antagonist; phenyl; administered; group
Prior art date: 2006-05-02
Legal status : Withdrawn

Application number

JP2009510053A

Other languages

English (en)

Japanese (ja)

Other versions

JP2009535430A5 (https=

Inventor

ジョセフケー．ベラノフ，

Original Assignee

コーセプトセラピューティクス，インコーポレイテッド

Priority date

2006-05-02

Filing date

2007-05-02

Publication date

2009-10-01

2007-05-02 Application filed by コーセプトセラピューティクス，インコーポレイテッド filed Critical コーセプトセラピューティクス，インコーポレイテッド

2009-10-01 Publication of JP2009535430A publication Critical patent/JP2009535430A/ja

2011-06-16 Publication of JP2009535430A5 publication Critical patent/JP2009535430A5/ja

Status Withdrawn legal-status Critical Current

Links

108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 90
102000003676 Glucocorticoid Receptors Human genes 0.000 title description 102
108090000079 Glucocorticoid Receptors Proteins 0.000 title description 102
239000005557 antagonist Substances 0.000 title description 77
238000000034 method Methods 0.000 claims abstract description 98
102000000588 Interleukin-2 Human genes 0.000 claims abstract description 89
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 85
239000003850 glucocorticoid receptor antagonist Substances 0.000 claims abstract description 63
229940126013 glucocorticoid receptor antagonist Drugs 0.000 claims abstract description 56
229960000890 hydrocortisone Drugs 0.000 claims abstract description 45
238000002560 therapeutic procedure Methods 0.000 claims abstract description 30
238000011282 treatment Methods 0.000 claims abstract description 25
206010054089 Depressive symptom Diseases 0.000 claims abstract description 15
230000000994 depressogenic effect Effects 0.000 claims abstract description 5
-1 steroid compound Chemical class 0.000 claims description 93
150000001875 compounds Chemical class 0.000 claims description 57
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 43
150000003431 steroids Chemical class 0.000 claims description 41
229960003248 mifepristone Drugs 0.000 claims description 32
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 21
230000003637 steroidlike Effects 0.000 claims description 16
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 13
230000037396 body weight Effects 0.000 claims description 13
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
230000004048 modification Effects 0.000 claims description 12
238000012986 modification Methods 0.000 claims description 12
239000000725 suspension Substances 0.000 claims description 10
239000000443 aerosol Substances 0.000 claims description 7
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 7
238000002347 injection Methods 0.000 claims description 7
239000007924 injection Substances 0.000 claims description 7
239000000829 suppository Substances 0.000 claims description 6
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 5
AFMXNPUMXZCVGU-CWNVBEKCSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] methanesulfonate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COS(C)(=O)=O)[C@@H]4[C@@H]3CCC2=C1 AFMXNPUMXZCVGU-CWNVBEKCSA-N 0.000 claims description 5
238000006467 substitution reaction Methods 0.000 claims description 5
150000003230 pyrimidines Chemical class 0.000 claims description 4
YMROUWDKBBTAPS-UHFFFAOYSA-N (2-methylpyridin-3-yl)methanamine Chemical compound CC1=NC=CC=C1CN YMROUWDKBBTAPS-UHFFFAOYSA-N 0.000 claims description 3
NQHBVDBKRQTWEH-UHFFFAOYSA-N 1-[(2-chlorophenyl)-diphenylmethyl]-3,5-dimethylpyrazole Chemical compound N1=C(C)C=C(C)N1C(C=1C(=CC=CC=1)Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 NQHBVDBKRQTWEH-UHFFFAOYSA-N 0.000 claims description 3
XKDZMKALJIYVNU-UHFFFAOYSA-N 1h-benzo[f]indazole Chemical compound C1=CC=C2C=C3C=NNC3=CC2=C1 XKDZMKALJIYVNU-UHFFFAOYSA-N 0.000 claims description 3
ACRGIRLCXXEJCS-UHFFFAOYSA-N 1h-indole-4-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1C=CN2 ACRGIRLCXXEJCS-UHFFFAOYSA-N 0.000 claims description 3
PHQYCUVRCSXPBF-UHFFFAOYSA-N 2,7-difluoro-9-phenyl-9-(5-sulfanylidene-1,2-dihydro-1,2,4-triazol-3-yl)-2h-fluoren-1-one Chemical group O=C1C(F)C=CC(C2=CC=C(F)C=C22)=C1C2(C=1C=CC=CC=1)C1=NC(S)=NN1 PHQYCUVRCSXPBF-UHFFFAOYSA-N 0.000 claims description 3
LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims description 3
AGUNPFIFLDXKPR-UHFFFAOYSA-N 2-trityl-1h-imidazole Chemical compound C1=CNC(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 AGUNPFIFLDXKPR-UHFFFAOYSA-N 0.000 claims description 3
DFXBSTBGWCEKSD-UHFFFAOYSA-N 4-[2-[tris(4-chlorophenyl)methoxy]ethyl]morpholine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(Cl)=CC=1)(C=1C=CC(Cl)=CC=1)OCCN1CCOCC1 DFXBSTBGWCEKSD-UHFFFAOYSA-N 0.000 claims description 3
POAVRNPUPPJLKZ-UHFFFAOYSA-N 6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulen-11-ol Chemical compound C1CC2=CC=CC=C2C(O)C2=CC=CC=C21 POAVRNPUPPJLKZ-UHFFFAOYSA-N 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 3
150000001448 anilines Chemical class 0.000 claims description 3
239000004305 biphenyl Substances 0.000 claims description 3
235000010290 biphenyl Nutrition 0.000 claims description 3
125000006267 biphenyl group Chemical group 0.000 claims description 3
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical group ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 3
FXKHIMPBOCLMFP-UHFFFAOYSA-N cyclopenta[f]indazole Chemical compound C=1C2=CN=NC2=CC2=CC=CC2=1 FXKHIMPBOCLMFP-UHFFFAOYSA-N 0.000 claims description 3
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 3
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 claims description 3
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 3
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 3
239000007921 spray Substances 0.000 claims description 3
150000004961 triphenylmethanes Chemical class 0.000 claims description 3
NTIQESMLXCAPAT-FGRBEGKDSA-N (2r,4as,10ar)-4a-benzyl-1-(2-chloroethynyl)-2,3,4,9,10,10a-hexahydro-1h-phenanthrene-2,7-diol Chemical compound C([C@]12CC[C@H](C([C@H]2CCC=2C1=CC=C(O)C=2)C#CCl)O)C1=CC=CC=C1 NTIQESMLXCAPAT-FGRBEGKDSA-N 0.000 claims description 2
WDSPVCXWXOIFRA-HUVFLSCGSA-N (2r,4as,10ar)-4a-benzyl-2-prop-1-ynyl-1,3,4,9,10,10a-hexahydrophenanthrene-2,7-diol Chemical compound C([C@]12CC[C@](C[C@H]2CCC=2C1=CC=C(O)C=2)(O)C#CC)C1=CC=CC=C1 WDSPVCXWXOIFRA-HUVFLSCGSA-N 0.000 claims description 2
PJDWNSYGMXODTB-UHFFFAOYSA-N 1,2,3,4,4a,4b,5,6-octahydrophenanthrene Chemical compound C1=CCCC2C(CCCC3)C3=CC=C21 PJDWNSYGMXODTB-UHFFFAOYSA-N 0.000 claims description 2
YIWVYEMVUUIDFI-UHFFFAOYSA-N 1-[(2-chlorophenyl)-diphenylmethyl]-2-methylimidazole Chemical group CC1=NC=CN1C(C=1C(=CC=CC=1)Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 YIWVYEMVUUIDFI-UHFFFAOYSA-N 0.000 claims description 2
BEUDCHGZCTUAOG-UHFFFAOYSA-N 6h-benzo[c]chromene Chemical class C1=CC=C2COC3=CC=CC=C3C2=C1 BEUDCHGZCTUAOG-UHFFFAOYSA-N 0.000 claims description 2
230000001548 androgenic effect Effects 0.000 claims description 2
BLOFVNRXXISVRW-SPIKMXEPSA-N (z)-but-2-enedioic acid;2-[4-[2-[tris(4-chlorophenyl)methoxy]ethyl]piperazin-1-yl]ethanol Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C1CN(CCO)CCN1CCOC(C=1C=CC(Cl)=CC=1)(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BLOFVNRXXISVRW-SPIKMXEPSA-N 0.000 claims 1
MLRAJZNPKPVUDQ-UHFFFAOYSA-N 3-sulfanyl-1,2-dihydrotriazole Chemical compound SN1NNC=C1 MLRAJZNPKPVUDQ-UHFFFAOYSA-N 0.000 claims 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
LVBREWKFQYTCQO-UHFFFAOYSA-N N1=CC=C(C=C1)CNC(=O)C1=CC=2C=CC3=CC=CC=C3C2C=C1 Chemical compound N1=CC=C(C=C1)CNC(=O)C1=CC=2C=CC3=CC=CC=C3C2C=C1 LVBREWKFQYTCQO-UHFFFAOYSA-N 0.000 claims 1
230000002441 reversible effect Effects 0.000 abstract description 6
239000000203 mixture Substances 0.000 description 48
230000000694 effects Effects 0.000 description 37
239000003862 glucocorticoid Substances 0.000 description 35
208000024891 symptom Diseases 0.000 description 35
239000003814 drug Substances 0.000 description 30
238000009472 formulation Methods 0.000 description 23
208000024714 major depressive disease Diseases 0.000 description 22
229940079593 drug Drugs 0.000 description 20
210000004027 cell Anatomy 0.000 description 18
125000004404 heteroalkyl group Chemical group 0.000 description 18
239000000556 agonist Substances 0.000 description 16
125000000217 alkyl group Chemical group 0.000 description 16
125000003118 aryl group Chemical group 0.000 description 16
230000027455 binding Effects 0.000 description 15
102000004127 Cytokines Human genes 0.000 description 14
108090000695 Cytokines Proteins 0.000 description 14
229940037128 systemic glucocorticoids Drugs 0.000 description 14
238000003556 assay Methods 0.000 description 13
230000002354 daily effect Effects 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
208000033763 Familial hyperaldosteronism type I Diseases 0.000 description 12
102000000589 Interleukin-1 Human genes 0.000 description 12
108010002352 Interleukin-1 Proteins 0.000 description 12
201000011266 glucocorticoid-remediable aldosteronism Diseases 0.000 description 12
108090000375 Mineralocorticoid Receptors Proteins 0.000 description 11
102100021316 Mineralocorticoid receptor Human genes 0.000 description 11
125000000753 cycloalkyl group Chemical group 0.000 description 11
125000000592 heterocycloalkyl group Chemical group 0.000 description 11
125000001424 substituent group Chemical group 0.000 description 11
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
125000005842 heteroatom Chemical group 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
238000003745 diagnosis Methods 0.000 description 9
125000001072 heteroaryl group Chemical group 0.000 description 9
230000036651 mood Effects 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
125000002947 alkylene group Chemical group 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
208000024732 dysthymic disease Diseases 0.000 description 8
230000006870 function Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
206010012374 Depressed mood Diseases 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
230000008512 biological response Effects 0.000 description 7
239000003446 ligand Substances 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
206010026749 Mania Diseases 0.000 description 6
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
125000004474 heteroalkylene group Chemical group 0.000 description 6
230000003993 interaction Effects 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
238000012544 monitoring process Methods 0.000 description 6
230000028327 secretion Effects 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
210000002700 urine Anatomy 0.000 description 6
241000700159 Rattus Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
150000001886 cortisols Chemical class 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
201000010099 disease Diseases 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
201000000980 schizophrenia Diseases 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
201000005255 adrenal gland hyperfunction Diseases 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
239000007859 condensation product Substances 0.000 description 4
230000003203 everyday effect Effects 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
206010073071 hepatocellular carcinoma Diseases 0.000 description 4
206010020765 hypersomnia Diseases 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000002502 liposome Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
239000004005 microsphere Substances 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
229940044551 receptor antagonist Drugs 0.000 description 4
239000002464 receptor antagonist Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000003765 sweetening agent Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010010144 Completed suicide Diseases 0.000 description 3
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
208000020401 Depressive disease Diseases 0.000 description 3
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
229920000084 Gum arabic Polymers 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010021030 Hypomania Diseases 0.000 description 3
102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
208000019022 Mood disease Diseases 0.000 description 3
208000001431 Psychomotor Agitation Diseases 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
108010085012 Steroid Receptors Proteins 0.000 description 3
229920001615 Tragacanth Polymers 0.000 description 3
208000021017 Weight Gain Diseases 0.000 description 3
235000010489 acacia gum Nutrition 0.000 description 3
239000000205 acacia gum Substances 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
239000003086 colorant Substances 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
238000013461 design Methods 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000003599 food sweetener Nutrition 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000003635 glucocorticoid antagonist Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
125000001183 hydrocarbyl group Chemical group 0.000 description 3
125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
206010022437 insomnia Diseases 0.000 description 3
238000009533 lab test Methods 0.000 description 3
125000005647 linker group Chemical group 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000003340 mental effect Effects 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
102000005969 steroid hormone receptors Human genes 0.000 description 3
239000000126 substance Substances 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
230000004584 weight gain Effects 0.000 description 3
235000019786 weight gain Nutrition 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
HFDGABTZPISMDD-IEVXGSBISA-N (6r,8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-6,13-dimethylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one Chemical compound C([C@H]1[C@@H]2C[C@H](C3=CC(=O)CCC3=C2[C@H](C[C@@]11C)C=2C=CC(=CC=2)N(C)C)C)C[C@]21CCCO2 HFDGABTZPISMDD-IEVXGSBISA-N 0.000 description 2
WFPOBMHQGIPWFB-GCLUAJDJSA-N (7s,8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-7,13-dimethylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one Chemical compound C([C@@H]1[C@]2(C)C[C@@H](C3=C4CCC(=O)C=C4C[C@@H]([C@@H]13)C)C=1C=CC(=CC=1)N(C)C)C[C@@]21CCCO1 WFPOBMHQGIPWFB-GCLUAJDJSA-N 0.000 description 2
YNCNEPHWJBSKJJ-OIHMHFBDSA-N (8r,9s,10r,13s,14s,17s)-17-(2-hydroxyacetyl)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 YNCNEPHWJBSKJJ-OIHMHFBDSA-N 0.000 description 2
IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 2
DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
NZXIIYFKLMEBEO-UHFFFAOYSA-N 1-[tris(4-chlorophenyl)methyl]-3-[tris(4-chlorophenyl)methylsulfanyl]-1,2,4-triazole Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(Cl)=CC=1)(C=1C=CC(Cl)=CC=1)SC1=NN(C(C=2C=CC(Cl)=CC=2)(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C=N1 NZXIIYFKLMEBEO-UHFFFAOYSA-N 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
YNCNEPHWJBSKJJ-UHFFFAOYSA-N 10-nordeoxycorticosterone Natural products O=C1CCC2C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 YNCNEPHWJBSKJJ-UHFFFAOYSA-N 0.000 description 2
WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 2
NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 description 2
NYPFYLJVPVYYPW-UHFFFAOYSA-N 2-[imidazol-1-yl(diphenyl)methyl]pyridine Chemical compound C1=NC=CN1C(C=1N=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 NYPFYLJVPVYYPW-UHFFFAOYSA-N 0.000 description 2
RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
206010050013 Abulia Diseases 0.000 description 2
206010001497 Agitation Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
206010011971 Decreased interest Diseases 0.000 description 2
206010013496 Disturbance in attention Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010020710 Hyperphagia Diseases 0.000 description 2
206010022004 Influenza like illness Diseases 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000027099 Paranoid disease Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
206010038743 Restlessness Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
102000011923 Thyrotropin Human genes 0.000 description 2
108010061174 Thyrotropin Proteins 0.000 description 2
ATNWRUJPJUBMHC-HOGMHMTRSA-N [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] methanesulfonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COS(C)(=O)=O)(O)[C@@]1(C)C[C@@H]2O ATNWRUJPJUBMHC-HOGMHMTRSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
230000036528 appetite Effects 0.000 description 2
235000019789 appetite Nutrition 0.000 description 2
239000000305 astragalus gummifer gum Substances 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003240 coconut oil Substances 0.000 description 2
235000019864 coconut oil Nutrition 0.000 description 2
239000013256 coordination polymer Substances 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
230000034994 death Effects 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
230000003001 depressive effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
230000009429 distress Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
239000000284 extract Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000012634 fragment Substances 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 2
230000005934 immune activation Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000007689 inspection Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
206010027175 memory impairment Diseases 0.000 description 2
208000021039 metastatic melanoma Diseases 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
235000020830 overeating Nutrition 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
102000003998 progesterone receptors Human genes 0.000 description 2
108090000468 progesterone receptors Proteins 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000012439 solid excipient Substances 0.000 description 2
235000011069 sorbitan monooleate Nutrition 0.000 description 2
239000001593 sorbitan monooleate Substances 0.000 description 2
229940035049 sorbitan monooleate Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000035882 stress Effects 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
125000004417 unsaturated alkyl group Chemical group 0.000 description 2
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
229940045145 uridine Drugs 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
DFELGYQKEOCHOA-RBXNTRDFSA-N (11r,13s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CCC3C3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-RBXNTRDFSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
XMAYWYJOQHXEEK-JYFHCDHNSA-N (2S,4S)-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-JYFHCDHNSA-N 0.000 description 1
SEJUQQOPVAUETF-QHLBDZCJSA-N (2r,6r,11s)-3-(cyclopropylmethyl)-6-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2h)-one Chemical compound C([C@@]1([C@@H]([C@@H]2C(=O)C=3C1=CC(O)=CC=3)C)CC)CN2CC1CC1 SEJUQQOPVAUETF-QHLBDZCJSA-N 0.000 description 1
SEOPOTXFVGEDGX-UPHHSBJESA-N (4bs,7r,8ar)-4b-benzyl-7-hydroxy-7-prop-1-ynyl-n-(pyridin-3-ylmethyl)-5,6,8,8a,9,10-hexahydrophenanthrene-2-carboxamide Chemical compound C([C@]12CC[C@](C[C@H]2CCC=2C1=CC=C(C=2)C(=O)NCC=1C=NC=CC=1)(O)C#CC)C1=CC=CC=C1 SEOPOTXFVGEDGX-UPHHSBJESA-N 0.000 description 1
ZCAUIZYRNPHJJO-CAMMJAKZSA-N (8s,10s,13s,14s)-10,13-dimethyl-1,2,6,7,8,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]12)CC3=CC(=O)CC[C@]3(C)C1=CC[C@@]1(C)[C@H]2CCC1 ZCAUIZYRNPHJJO-CAMMJAKZSA-N 0.000 description 1
DFELGYQKEOCHOA-BZAFBGKRSA-N (8s,11r,13s,14s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-BZAFBGKRSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
RMAFFDDZXBTOQO-SPIKMXEPSA-N (Z)-but-2-enedioic acid piperazine Chemical compound C1CNCCN1.OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O RMAFFDDZXBTOQO-SPIKMXEPSA-N 0.000 description 1
125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
LZTNPKSJHKBDIN-UHFFFAOYSA-N 1-[(2-chlorophenyl)-diphenylmethyl]-1,2,4-triazole Chemical compound ClC1=CC=CC=C1C(N1N=CN=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZTNPKSJHKBDIN-UHFFFAOYSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
KDTQBESFYGHFDV-UHFFFAOYSA-N 4aH-benzo[c]chromene Chemical class C1=CC=CC2OC=C(C=CC=C3)C3=C21 KDTQBESFYGHFDV-UHFFFAOYSA-N 0.000 description 1
YVBZQWWFVXTCFM-UHFFFAOYSA-N 5-[(2-chlorophenyl)-diphenylmethyl]-1h-1,2,4-triazole Chemical compound ClC1=CC=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=NNC=N1 YVBZQWWFVXTCFM-UHFFFAOYSA-N 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
206010071070 Autophobia Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
101100272852 Clostridium botulinum (strain Langeland / NCTC 10281 / Type F) F gene Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
208000014311 Cushing syndrome Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010066392 Fear of death Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
229940123127 Glucocorticoid agonist Drugs 0.000 description 1
229940117965 Glucocorticoid receptor modulator Drugs 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
208000037171 Hypercorticoidism Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108010092277 Leptin Proteins 0.000 description 1
102000016267 Leptin Human genes 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
108010049175 N-substituted Glycines Chemical class 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229910003849 O-Si Inorganic materials 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
229910003872 O—Si Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
206010037180 Psychiatric symptoms Diseases 0.000 description 1
206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229940127412 Steroid Receptor Antagonists Drugs 0.000 description 1
208000013200 Stress disease Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010043169 Tearfulness Diseases 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
102000014034 Transcortin Human genes 0.000 description 1
108010011095 Transcortin Proteins 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
102000016540 Tyrosine aminotransferases Human genes 0.000 description 1
108010042606 Tyrosine transaminase Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
208000017515 adrenocortical insufficiency Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
238000013019 agitation Methods 0.000 description 1
108700025316 aldesleukin Proteins 0.000 description 1
229960005310 aldesleukin Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000005237 alkyleneamino group Chemical group 0.000 description 1
125000005238 alkylenediamino group Chemical group 0.000 description 1
125000005530 alkylenedioxy group Chemical group 0.000 description 1
125000005529 alkyleneoxy group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000003098 androgen Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003418 antiprogestin Substances 0.000 description 1
229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
239000002812 cholic acid derivative Substances 0.000 description 1
229960004022 clotrimazole Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000012502 diagnostic product Substances 0.000 description 1
235000001916 dieting Nutrition 0.000 description 1
230000037228 dieting effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
230000002461 excitatory amino acid Effects 0.000 description 1
239000003257 excitatory amino acid Substances 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002332 glycine derivatives Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
108010046780 hydrocortisone receptor Proteins 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
230000009390 immune abnormality Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
102000027411 intracellular receptors Human genes 0.000 description 1
108091008582 intracellular receptors Proteins 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
238000003367 kinetic assay Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
229940039781 leptin Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
230000027928 long-term synaptic potentiation Effects 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000004766 neurogenesis Effects 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
GQYBCIHRWMPOOF-UHFFFAOYSA-N p-hydroxyphenylpyruvic acid Natural products OC(=O)C(O)=CC1=CC=C(O)C=C1 GQYBCIHRWMPOOF-UHFFFAOYSA-N 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
239000003973 paint Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000003623 progesteronic effect Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
208000037921 secondary disease Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000020685 sleep-wake disease Diseases 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
150000003515 testosterones Chemical class 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000005309 thioalkoxy group Chemical group 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000014616 translation Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
DNHDRUMZDHWHKG-UHFFFAOYSA-N wieland–miescher ketone Chemical class C1CC(=O)C=C2CCCC(=O)C21C DNHDRUMZDHWHKG-UHFFFAOYSA-N 0.000 description 1